BR112013031871A2 - composto; veículo termossensível; uso de um composto; sistema para a aplicação de fármaco; sistema de imagens; e sistema combinado para a aplicação de fármaco - Google Patents

composto; veículo termossensível; uso de um composto; sistema para a aplicação de fármaco; sistema de imagens; e sistema combinado para a aplicação de fármaco

Info

Publication number
BR112013031871A2
BR112013031871A2 BR112013031871A BR112013031871A BR112013031871A2 BR 112013031871 A2 BR112013031871 A2 BR 112013031871A2 BR 112013031871 A BR112013031871 A BR 112013031871A BR 112013031871 A BR112013031871 A BR 112013031871A BR 112013031871 A2 BR112013031871 A2 BR 112013031871A2
Authority
BR
Brazil
Prior art keywords
compound
drug delivery
heat sensitive
delivery system
drug
Prior art date
Application number
BR112013031871A
Other languages
English (en)
Inventor
Holger Gruell
Johan Lub
Sander Langereis
Original Assignee
Koninkl Philips Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninkl Philips Nv filed Critical Koninkl Philips Nv
Publication of BR112013031871A2 publication Critical patent/BR112013031871A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

resumo composto; veículo termossensível; uso de um composto; sistema para a aplicação de fármaco; sistema de imagens; e sistema combinado para a aplicação de fármaco são revelados compostos lipidomiméticos da fórmula i fórmula i em que: g representa um grupo de acordo com a fórmula ii: ho-ch2-{ch(oh)-ch2-o}m-ch2-{c(=o)-o-ch2}q- fórmula ii cada n sendo independentemente um número inteiro de 1-30; m é um número inteiro de 1-10; q é 0 ou 1. esses compostos podem ser adicionados à bicamada lipídica de lipossomos termossensíveis, com o propósito de ajudar na prevenção do vazamento o conteúdo dos lipossomos a 37ºc, e retardar o clearance da circulação.
BR112013031871A 2011-06-16 2012-06-06 composto; veículo termossensível; uso de um composto; sistema para a aplicação de fármaco; sistema de imagens; e sistema combinado para a aplicação de fármaco BR112013031871A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11170139A EP2535326A1 (en) 2011-06-16 2011-06-16 Novel lipidomimetic compounds and uses thereof
PCT/IB2012/052829 WO2012172457A1 (en) 2011-06-16 2012-06-06 Novel lipidomimetic compounds and uses thereof

Publications (1)

Publication Number Publication Date
BR112013031871A2 true BR112013031871A2 (pt) 2016-12-13

Family

ID=46321195

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013031871A BR112013031871A2 (pt) 2011-06-16 2012-06-06 composto; veículo termossensível; uso de um composto; sistema para a aplicação de fármaco; sistema de imagens; e sistema combinado para a aplicação de fármaco

Country Status (7)

Country Link
US (1) US9061062B2 (pt)
EP (2) EP2535326A1 (pt)
JP (1) JP6085296B2 (pt)
CN (2) CN103619802B (pt)
BR (1) BR112013031871A2 (pt)
RU (1) RU2014101173A (pt)
WO (1) WO2012172457A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2535326A1 (en) * 2011-06-16 2012-12-19 Koninklijke Philips Electronics N.V. Novel lipidomimetic compounds and uses thereof
WO2014037498A2 (en) * 2012-09-07 2014-03-13 Bracco Imaging Spa Paramagnetic solid lipid nanoparticles (pslns) containing metal amphiphilic complexes for mri.
US9663432B2 (en) 2012-12-28 2017-05-30 Dow Corning Toray Co., Ltd. High-purity monoalkenyl-containing glycerin derivative and method of manufacturing same
CN103304445B (zh) * 2013-05-27 2014-10-22 南京大学 阳离子聚甘油酯类脂质及其合成方法和应用
EP3592728A1 (en) 2017-03-07 2020-01-15 Translate Bio, Inc. Polyanionic delivery of nucleic acids

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JP3017035B2 (ja) * 1993-12-22 2000-03-06 花王株式会社 蛋白質含有食品の改質剤及び改質剤組成物、並びに改質剤で処理した小麦粉製品
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
US7112337B2 (en) * 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
CN100379404C (zh) * 2003-02-28 2008-04-09 阿尔扎公司 用于减少脂质体诱导的补体激活的脂质体组合物
WO2010029469A1 (en) * 2008-09-10 2010-03-18 Koninklijke Philips Electronics N.V. Drug carrier providing mri contrast enhancement
EP2535326A1 (en) * 2011-06-16 2012-12-19 Koninklijke Philips Electronics N.V. Novel lipidomimetic compounds and uses thereof

Also Published As

Publication number Publication date
JP6085296B2 (ja) 2017-02-22
US9061062B2 (en) 2015-06-23
CN108276285A (zh) 2018-07-13
JP2014522417A (ja) 2014-09-04
EP2535326A1 (en) 2012-12-19
US20140127135A1 (en) 2014-05-08
RU2014101173A (ru) 2015-07-27
WO2012172457A1 (en) 2012-12-20
CN103619802B (zh) 2016-01-20
EP2720999A1 (en) 2014-04-23
EP2720999B1 (en) 2017-08-23
CN103619802A (zh) 2014-03-05

Similar Documents

Publication Publication Date Title
BR112013031871A2 (pt) composto; veículo termossensível; uso de um composto; sistema para a aplicação de fármaco; sistema de imagens; e sistema combinado para a aplicação de fármaco
BR112013000273A2 (pt) derivados de imidazopiridina, processo para a preparação dos mesmos e uso terapêutico dos mesmos
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
CO6540003A2 (es) Inhibidor de bromodominio de benzodiazepina
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
BR112015008480A2 (pt) compostos de benzeno substituído
BR112014002946A2 (pt) sistema de travamento mecânico para painéis de piso
AR088622A1 (es) 18-METIL-6,7-METILEN-3-OXO-17-PREGN-4-EN-21,17b-CARBOLACTONA, PREPARADOS FARMACEUTICOS QUE CONTIENEN LOS COMPUESTOS MENCIONADOS Y SU USO EN LA TERAPIA DE LA ENDOMETRIOSIS
DOP2010000387A (es) Compuestos pirazolicos 436
BR112014012358A2 (pt) 2-oxo-1,3-dioxolano-4-carboxamidas, sua preparação e uso
DOP2010000259A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
BR112015008447A2 (pt) métodos para tratar câncer
BR112015022566A2 (pt) composto e composição farmacêutica
BR112014007193A2 (pt) derivados de pirazoloquinolinona, preparação dos mesmos e uso terapêutico dos mesmos
BR112014014137A2 (pt) sistema de liberação transdérmica compreendendo buprenorfina
BR112015028212A2 (pt) derivado de fenol e método de preparação e utilização dos mesmos na medicina
BR112014013661A8 (pt) derivados de nucleosídeos 2’,4’-difluoro-2’-metil substituídos como inibidores de replicação de hcv-rna
BR112013031405A2 (pt) piridopirazinas substituídas como novos inibidores de syk
CO6920294A2 (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112017002214A2 (pt) composto de fórmula (i), composição farmacêutica e usos de um composto
AR084597A1 (es) Uso de estabilizadores de glutamina
BR112015022092A2 (pt) derivado de di-hidropiridazina-3,5-diona
BR112013019160A2 (pt) novos compostos, composição farmacêutica, uso, processos e métodos
UY31864A (es) Derivados de urea hetericíclica y métodos de uso de los mismos-332

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/14 (2006.01), A61K 9/127 (2006.01), A61K 4